Larimar Therapeutics Inc’s filing revealed that its Director Flynn James E acquired Company’s shares for reported $30.0 million on Jul 31 ’25. In the deal valued at $3.20 per share,9,375,000 shares were bought. As a result of this transaction, Flynn James E now holds 9,538,945 shares worth roughly $31.76 million.
Truist initiated its Larimar Therapeutics Inc [LRMR] rating to a Buy in a research note published on January 29, 2025; the price target was $18. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid October with a ‘”an Outperform”‘ rating. Wedbush began covering LRMR with “an Outperform” recommendation on October 03, 2024. H.C. Wainwright started covering the stock on October 02, 2024. It rated LRMR as “a Buy”.
Price Performance Review of LRMR
On Monday, Larimar Therapeutics Inc [NASDAQ:LRMR] saw its stock fall -0.89% to $3.33. Over the last five days, the stock has lost -4.03%. Larimar Therapeutics Inc shares have fallen nearly -15.91% since the year began. Nevertheless, the stocks have fallen -12.60% over the past one year.
How much short interest is there in Larimar Therapeutics Inc?
A steep rise in short interest was recorded in Larimar Therapeutics Inc stocks on 2025-12-15, dropping by -2.15 million shares to a total of 7.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 10.08 million shares. There was a decline of -27.18%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 04, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $16 price target.
